Thursday, October 15, 2026

KLA Projects Mid-to-High Teens Growth in Advanced Packaging as AI Chips Drive Equipment Demand

KLA Corp. forecasts mid-to-high teens growth in advanced packaging equipment for calendar 2026, outpacing broader semiconductor industry growth. The packaging equipment maker expanded indium phosphide capacity by over 20% in Q4 alone as AI chip manufacturers race to improve interconnect density. Advanced packaging is emerging as a competitive moat for chipmakers unable to access leading-edge process nodes.

KLA Projects Mid-to-High Teens Growth in Advanced Packaging as AI Chips Drive Equipment Demand
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

KLA Corp. expects its advanced packaging equipment business to grow in the mid-to-high teens percentage range through calendar 2026, CEO Michael E. Hurlston told investors. The projection signals strong demand as AI chip manufacturers prioritize packaging innovation over traditional node shrinks.

KLA increased indium phosphide capacity by more than 20% in the December quarter alone. Indium phosphide enables high-speed optical interconnects critical for AI data center infrastructure. Most initial 1.6-terabit transceivers use electro-absorption modulated lasers, and 200-gigabit lane speeds are exceeding expectations, Hurlston said.

Advanced packaging allows chipmakers to stack memory closer to processors and connect multiple dies in a single package. This approach delivers performance gains without requiring access to TSMC's most advanced manufacturing nodes, which remain supply-constrained and expensive.

The strategic shift creates opportunities for equipment makers specializing in packaging technologies. KLA's stock has outperformed the broader semiconductor equipment index as investors recognize packaging as a bottleneck. Companies unable to secure leading-edge foundry capacity are investing heavily in packaging to maintain competitive AI chip performance.

The trend extends beyond AI accelerators. High-bandwidth memory packaging, chiplet integration, and 3D stacking require specialized metrology and inspection equipment. KLA's packaging revenues are growing faster than its core semiconductor process control business, which remains cyclically exposed to memory chip demand.

For AI chip designers, packaging expertise is becoming a differentiator. Companies that optimize chip-to-chip interconnects can achieve better power efficiency and lower latency than competitors relying solely on process technology. This dynamic supports sustained equipment demand even if overall semiconductor capital expenditure moderates.

The advanced packaging market is projected to grow as percentage of total semiconductor equipment spending through 2026. Equipment makers with packaging portfolios—including KLA, ASML's assembly systems division, and Lam Research—are positioned to capture outsized share of industry investment as AI infrastructure buildout continues.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com